Recombinant Papio hamadryas CD44 antigen (CD44)

What is the CD44 antigen in Papio hamadryas and how does it compare to human CD44?

The CD44 antigen in Papio hamadryas (hamadryas baboon) is a multifunctional cell surface glycoprotein that shares significant homology with human CD44. It functions as an extracellular matrix receptor (also known as ECMR-III) and serves as a hyaluronate receptor involved in cell adhesion, migration, and immune responses. The protein features several alternative names including GP90 lymphocyte homing/adhesion receptor, Hermes antigen, and phagocytic glycoprotein 1 (PGP-1) . The full-length protein expression region typically spans amino acids 21-362, with functional domains that facilitate interactions with hyaluronic acid and other extracellular matrix components . While human CD44 shares many functional characteristics with the Papio hamadryas variant, researchers should be aware of species-specific variations that may affect experimental outcomes in comparative studies.

What is the amino acid sequence and structure of recombinant Papio hamadryas CD44?

The amino acid sequence of recombinant Papio hamadryas CD44 antigen is:
QIDLNITCRFEGIYHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPGEDCTSVTDLPNAFDGPITITIVNRDGTRYVKKGEYRTNPEDINPSSPTDDDVSSGSSSERSSTLGGYIFYNHFSTSPPIPDEDGPWITDSTDRTPATRDQGAFDPSGGSHTTHGSESAGHSHGSREGGANTTSGPLRTPQIPEWLIILASLLALALILAVCIAVNSRRRCGQKKKLVINNGNGAVEDRKSSGLNGEASKSQEMVHLVNKESSETPDQFMTADETRNLQNVDMKIGV

This sequence contains extracellular domains that interact with hyaluronic acid, a transmembrane region, and a cytoplasmic tail that mediates intracellular signaling. The structure features glycosylation sites and disulfide bonds that contribute to the protein's tertiary structure and functional properties. The protein's UniProt accession number is P14745, which researchers can reference for additional structural information and comparisons with CD44 variants from other species .

What are the optimal storage conditions for recombinant Papio hamadryas CD44?

For optimal preservation of recombinant Papio hamadryas CD44 antigen, storage at -20°C is recommended for regular use, while extended storage should be at -20°C or -80°C. The protein is typically supplied in a Tris-based buffer containing 50% glycerol, which has been optimized to maintain protein stability . Researchers should be aware that repeated freezing and thawing cycles can compromise protein integrity and functionality, so it is advisable to prepare working aliquots that can be stored at 4°C for up to one week . When preparing working solutions, it's essential to use sterile techniques and avoid introducing contaminants that might affect experimental outcomes or protein stability. Monitoring protein stability through activity assays after various storage periods can help establish optimal laboratory-specific protocols.

How can cross-reactivity issues be addressed when using anti-CD44 antibodies in non-human primate research?

A systematic approach to addressing cross-reactivity includes:

• Preliminary screening of multiple antibody clones against Papio hamadryas samples

• Validation of positive staining through comparison with known expression patterns

• Determination of optimal antibody concentrations through titration experiments

• Inclusion of appropriate isotype controls to confirm specificity

• Cell type-specific validation when working with heterogeneous samples

Researchers should be aware that even antibodies reported to cross-react might show differential binding to specific cell populations or may recognize different epitopes across species, potentially affecting functional studies . When possible, perform side-by-side comparisons with human samples to identify potential discrepancies in staining patterns or intensity.

How can recombinant Papio hamadryas CD44 be used in cancer stem cell research models?

Recombinant Papio hamadryas CD44 can serve as a valuable tool in cancer stem cell (CSC) research, particularly in comparative studies examining conservation of CSC markers across species. CD44 has been identified as one of the most significant CSC markers in multiple cancer types, often used in conjunction with other markers such as ALDH and EPCAM . Researchers can utilize recombinant Papio hamadryas CD44 in several advanced applications:

• Development of cross-species binding assays to evaluate the specificity of therapeutic antibodies targeting CD44

• Generation of standards for quantitative flow cytometry to detect CD44-positive cells in primate model systems

• Creation of competitive binding assays to characterize the interaction of CD44 with hyaluronic acid and other ligands

• Establishment of protein-protein interaction studies to identify conserved binding partners

Recent research has identified a highly positive correlation between ALDH high expression and CD44+/EPCAM+ cells in non-small cell lung cancer, with a Pearson's correlation coefficient of 0.69, suggesting that CD44 in combination with EPCAM might serve as a surface marker profile for identifying ALDH high cancer stem-like cells . This finding highlights the potential for using recombinant CD44 in developing assays to identify and isolate cancer stem cells in both human and non-human primate model systems.

What considerations are important when evaluating CD44 as a therapeutic target in translational research?

When evaluating CD44 as a therapeutic target in translational research using non-human primate models, several important considerations must be addressed. CD44 exists in multiple isoforms due to alternative splicing, with the CD44v6 variant being particularly relevant in cancer studies. A recent study characterized a novel engineered recombinant monoclonal anti-CD44v6 antibody (AbN44v6) for radio-immunotherapy (RIT) applications, demonstrating CD44v6-specific binding in vitro and successful growth inhibition in CD44v6-expressing tumor models .

Key considerations for translational research include:

• Isoform specificity: Determine which CD44 variants are expressed in the target tissue and ensure targeting specificity

• Expression patterns: Compare expression levels between normal and diseased tissues to establish a therapeutic window

• Functional redundancy: Assess whether other molecules might compensate for CD44 inhibition

• Species differences: Evaluate potential differences in CD44 glycosylation patterns or binding domain structures between humans and non-human primates

• Immunogenicity: Consider the potential for immune responses against therapeutic antibodies in different species

The study with AbN44v6 demonstrated that both 177Lu-AbN44v6 and 131I-AbN44v6 conjugates showed promising results as RIT candidates, with favorable biodistribution and dosimetry in vivo . These findings highlight the potential of targeting specific CD44 variants in cancer therapy while emphasizing the importance of comprehensive preclinical evaluation.

What methods can be used to assess the purity and activity of recombinant Papio hamadryas CD44?

Multiple analytical methods can be employed to assess the purity and activity of recombinant Papio hamadryas CD44 preparations:

• Purity Assessment:

  • SDS-PAGE analysis with Coomassie or silver staining to visualize protein bands

  • Western blotting with anti-CD44 antibodies to confirm identity

  • Size exclusion chromatography to detect aggregates or degradation products

  • Endotoxin testing using the LAL method to ensure levels remain below 1.0 EU/μg, which is critical for cell-based assays

• Activity Determination:

  • ELISA binding assays using anti-CD44 antibodies to confirm proper folding and epitope accessibility

  • Functional binding assays with hyaluronic acid to verify ligand-binding capacity

  • Cell adhesion assays to assess biological activity

  • Surface plasmon resonance to determine binding kinetics and affinity constants

For recombinant human CD44, functional ELISA has been used to demonstrate binding to mouse monoclonal anti-CD44 antibodies with EC50 values ranging from 11.89-14.94 ng/mL . Similar approaches can be adapted for Papio hamadryas CD44, though researchers should be aware that species-specific differences might affect antibody binding profiles and activity measurements. Inclusion of appropriate positive and negative controls in all assays is essential for accurate interpretation of results.

How should species-specific differences be accounted for when interpreting CD44 research results?

When interpreting CD44 research results across species, researchers must account for several potential sources of variation:

• Sequence variations: Despite high homology, amino acid differences between human and Papio hamadryas CD44 may affect ligand binding, antibody recognition, and signaling properties.

• Post-translational modifications: Differences in glycosylation patterns, which are critical for CD44 function, may exist between species and affect functional outcomes.

• Isoform distribution: The expression pattern of CD44 splice variants may differ between species or tissues, complicating direct comparisons.

• Interaction partners: The binding affinity of CD44 for hyaluronic acid and other ligands may vary between species, affecting downstream signaling pathways.

• Antibody cross-reactivity: As noted in cross-reactivity screening studies, antibodies raised against human CD44 may recognize different epitopes or show variable staining intensity in non-human primate samples .

To account for these differences, researchers should:

• Perform comparative analyses of CD44 sequences and structures across species of interest

• Validate functional assays using species-specific positive and negative controls

• Consider using multiple antibody clones targeting different epitopes to ensure comprehensive detection

• Include detailed species information in research reports to facilitate proper interpretation and reproducibility

• When possible, perform parallel experiments in both human and non-human primate systems to directly compare results

By systematically addressing these factors, researchers can more accurately translate findings between species and improve the predictive value of non-human primate models in human disease research.

How is CD44 being utilized in cancer stem cell identification and targeting strategies?

Recent research has established important connections between CD44 expression and cancer stem cell (CSC) characteristics, particularly in non-small cell lung cancer (NSCLC). Studies have demonstrated that CD44 in combination with EPCAM (CD44+/EPCAM+ cells) shows a strong correlation with ALDH high expression, a well-established CSC marker . This finding suggests that the CD44+/EPCAM+ immunophenotype could serve as a reliable surface marker profile for identifying cancer stem-like cells, potentially eliminating the need for more complex intracellular ALDH activity assays.

The development of novel engineered recombinant antibodies targeting specific CD44 variants, such as CD44v6, represents a significant advancement in therapeutic strategies. These antibodies can be conjugated with therapeutic radionuclides like 177Lu or 131I for radio-immunotherapy applications . In vitro studies using 3D tumor models have demonstrated CD44v6-specific growth inhibition in an activity-dependent manner, highlighting the potential of this approach for targeted cancer therapy.

Future directions in this field may include:

• Development of bispecific antibodies targeting CD44 in combination with other CSC markers

• Exploration of CD44-targeted immunotherapies in combination with conventional treatments

• Investigation of CD44's role in treatment resistance and metastasis

• Utilization of non-human primate models to evaluate the safety and efficacy of CD44-targeted therapies before human clinical trials

These approaches could significantly advance our understanding of CD44's role in cancer progression and lead to more effective targeted therapies.

What are the emerging applications of recombinant CD44 in immunology and inflammation research?

Beyond cancer research, CD44 plays crucial roles in immune responses and inflammatory processes. Human CD44 antigen interacts with hyaluronic acid to mediate cellular behaviors such as chemotaxis and attachment, particularly in lymphocytes . The cytoplasmic tail of CD44 interacts with the actin cytoskeleton through proteins like ankyrin and ERM (ezrin, radixin, moesin), facilitating cell migration and influencing inflammatory responses.

In inflammation research, CD44 has been shown to be involved in the recruitment and localization of immune cells at sites of injury or infection. Its expression is regulated by various inflammatory stimuli, including lipopolysaccharides (LPS) and cytokines, which enhance CD44 levels in monocytes and other immune cells . This regulation underscores CD44's role in orchestrating immune responses, as it not only aids in cell adhesion but also modulates the secretion of pro-inflammatory cytokines.

Emerging applications of recombinant CD44 in immunology research include:

• Development of in vitro models to study leukocyte trafficking and homing mechanisms

• Investigation of CD44's role in regulating the balance between pro- and anti-inflammatory responses

• Exploration of CD44-targeted approaches for treating inflammatory and autoimmune diseases

• Comparative studies of immune cell function across different primate species using species-specific CD44 reagents

These applications highlight the versatility of CD44 as a research tool and therapeutic target beyond the realm of cancer biology, opening new avenues for understanding and modulating immune responses in various disease contexts.